Atrium Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	36.68	18.62	10.9	9.76
Revenue Growth (YoY)	275.67%	70.85%	11.60%	-
Cost of Revenue	48.75	44.27	19.2	12.65
Gross Profit	-12.07	-25.65	-8.3	-2.89
Selling, General & Admin	42.15	23.98	4.92	3.5
Operating Expenses	47.39	23.98	4.92	3.5
Operating Income	-59.46	-49.63	-13.22	-6.39
Other Non Operating Income (Expenses)	0.63	-0.01	0	0
Pretax Income	-58.83	-49.64	-13.22	-6.39
Income Tax Expense	-0.14	-0.14	11.91	-
Net Income	-58.69	-49.5	-25.12	-6.39
Net Income to Common	-58.69	-49.5	-25.12	-6.39
Shares Outstanding (Basic)	17	16	-	-
Shares Outstanding (Diluted)	17	16	-	-
EPS (Basic)	-3.43	-3.19	-	-
EPS (Diluted)	-3.43	-3.19	-	-
Free Cash Flow	-64.71	-42.57	-22.82	56.07
Free Cash Flow Per Share	-3.78	-2.74	-	-
Gross Margin	-32.91%	-137.76%	-76.19%	-29.59%
Operating Margin	-162.10%	-266.57%	-121.30%	-65.40%
Profit Margin	-159.99%	-265.88%	-230.54%	-65.39%
Free Cash Flow Margin	-176.42%	-228.67%	-209.41%	574.25%
EBITDA	-59.04	-49.31	-13.05	-6.25
EBITDA Margin	-160.95%	-264.84%	-119.72%	-63.99%
D&A For EBITDA	0.42	0.32	0.17	0.14
EBIT	-59.46	-49.63	-13.22	-6.39
EBIT Margin	-162.10%	-266.57%	-121.30%	-65.40%

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.